MUC16 and ovarian serous adenocarcinoma: A total of 791 patients diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) were deemed eligible for inclusion in the study based on specific criteria, including disease progression, completion of second-line treatment, and the collection of more than six CA-125 data points and receiving a platinum-based regimen as their first-line therapy (S1 Fig).